Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice

摘要

To investigate the efficacy and safety of gatifloxacin (400 mg/day) on chronic prostatitis or cystitis, 453 patients with prostatitis (NIH category II or IIIa) (N= 149, mean 45.8 +/- 13.3 years) and cystitis (N= 304, mean 53.8 +/- 14.3 years) were enrolled. Total NIH CPSI score and symptom score for cystitis decreased from 20.3 to 9.9 (response rate 86.7%, 95% CI 80.2-93.2%) and from 6.2 to 1.8 (response rate 83.2%, 95% CI 78.7-87.7%), respectively. In the overall clinical efficacy, 71.2% and 88.4% of the patients with prostatitis and cystitis were responders, respectively. Of the patients, 15.7% reported insignificant adverse events. These results suggest that gatifloxacin was well tolerated and improved the clinical outcomes in patients with chronic prostatitis or cystitis. (c) 2006 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.